ArticleCureus2025
A Prospective Assessment of Helicobacter pylori Eradication Regimens in Treatment-Naïve Patients With Peptic Ulcer Disease.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background
objectiveTo prospectively evaluate and compare the efficacy of various first-line METHODOLOGY: A prospective observational study was conducted from October 2023 to September 2024 at the Department of Gastroenterology, Azad Jammu and Kashmir Medical College and Abbas Institute of Medical Sciences, Muzaffarabad. A total of 252 endoscopically confirmed, treatment-naïve PUD patients were enrolled and assigned to one of the three regimens using a rotational system. Eradication success was evaluated at 6 weeks post-treatment via urea breath or stool antigen test. Antibiotic resistance was assessed using culture and sensitivity testing from gastric biopsies. Logistic regression was used to identify predictors of eradication success.
resultsAmong 252 patients, 84 (33.33%) received standard triple therapy, 83 (32.94%) received bismuth-based quadruple therapy, and 85 (33.73%) received concomitant therapy. Overall,
conclusionConcomitant and bismuth-based quadruple therapies are superior to standard triple therapy in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.